These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8961074)

  • 1. Moexipril versus captopril in patients with mild to moderate hypertension.
    Stimpel M; Koch B; Jansen T; Fox A; Loh I
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):769-73. PubMed ID: 8961074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause.
    Agabiti-Rosei E; Ambrosioni E; Pirelli A; Stimpel M; Zanchetti A
    Eur J Clin Pharmacol; 1999 May; 55(3):185-9. PubMed ID: 10379633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide).
    Stimpel M; Koch B; Oparil S
    Cardiology; 1998 May; 89(4):271-6. PubMed ID: 9643274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients.
    Persson B; Stimpel M
    Eur J Clin Pharmacol; 1996; 50(4):259-64. PubMed ID: 8803515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension.
    White WB; Koch B; Stimpel M
    Am J Ther; 1997 Apr; 4(4):123-9. PubMed ID: 10423601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring.
    White WB; Whelton A; Fox AA; Stimpel M; Kaihlanen PM
    J Clin Pharmacol; 1995 Mar; 35(3):233-8. PubMed ID: 7608310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moexipril. A review of its use in the management of essential hypertension.
    Brogden RN; Wiseman LR
    Drugs; 1998 Jun; 55(6):845-60. PubMed ID: 9617599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil.
    Abernethy DR; Fox AA; Stimpel M
    J Clin Pharmacol; 1995 Aug; 35(8):794-9. PubMed ID: 8522636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension.
    Stimpel M; Koch B; Dickstein K
    Cardiology; 1996; 87(4):313-8. PubMed ID: 8793166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of the new angiotensin-converting enzyme inhibitor moexipril on the circadian rhythms of arterial pressure in hypertension patients].
    Ol'binskaia LI; Andrushchishina TB
    Ter Arkh; 1997; 69(3):58-61. PubMed ID: 9229835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension.
    Stimpel M; Koch B
    J Hum Hypertens; 1997 Feb; 11(2):133-7. PubMed ID: 9140801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide.
    Chrysant SG; Stimpel M
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):384-90. PubMed ID: 9514183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibitors as initial monotherapy in severe hypertension. Quinapril and captopril.
    Frishman WH; Greenberg S
    Am J Hypertens; 1991 Oct; 4(10 Pt 1):827-31. PubMed ID: 1747216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between moexipril and atenolol in obese postmenopausal women with hypertension.
    Stimpel M; Koch B; Weber MA
    Maturitas; 1998 Sep; 30(1):69-77. PubMed ID: 9819786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.
    White WB; Stimpel M
    J Hum Hypertens; 1995 Nov; 9(11):879-84. PubMed ID: 8583466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.
    Persson B; Widgren BR; Fox A; Stimpel M
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):73-8. PubMed ID: 7564369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
    Chrysant SG; Fox AA; Stimpel M
    Am J Hypertens; 1995 Apr; 8(4 Pt 1):418-21. PubMed ID: 7619356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of quinapril vs. captopril in treatment of moderate to severe hypertension.
    Schnaper HW
    Angiology; 1989 Apr; 40(4 Pt 2):389-95. PubMed ID: 2650582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of moexipril in the treatment of hypertension.
    White WB; Fox AA; Stimpel M
    J Hum Hypertens; 1994 Dec; 8(12):917-21. PubMed ID: 7884791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin excretion rate and metabolic modifications in patients with essential hypertension. Effects of two angiotensin converting enzyme inhibitors.
    Puig JG; Mateos FA; Ramos TH; Lavilla MP; Capitán MC; Gil A
    Am J Hypertens; 1994 Jan; 7(1):46-51. PubMed ID: 8136110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.